Leadership Team

Hideo is a renowned drug developer with more than 20 years’ experience as a physician-scientist at biopharmaceutical companies and academia with particular expertise in early- and late-phase drug development in cardiovascular, metabolic, ophthalmology, neuroscience, oncology, and rare diseases. He has taken many novel molecules into humans for the first time and has contributed to more than 12 successful INDs, CTAs, and regulatory approval submissions. Prior to joining Affinia, Hideo was at Johnson & Johnson (J&J) where he was most recently global vice president (VP) and head of R&D for ophthalmology, and before that, global VP and head of translational & experimental medicine for cardiometabolic disease. Before J&J, Hideo had successful careers at Merck and Harvard Medical School. A patent holder and recipient of numerous academic and professional honors, research awards, and grants, he is an author on more than 60 manuscripts, reviews, and abstracts. Hideo earned his medical degree and a Ph.D. in neuroscience from the Mt. Sinai Icahn School of Medicine and a bachelor of science degree from Yale University. He trained as a clinical endocrinologist and is board certified in endocrinology, diabetes, and metabolism.